Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 23954088)

1.

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI.

Eur Urol. 2014 Jun;65(6):1191-7. doi: 10.1016/j.eururo.2013.07.006. Epub 2013 Jul 26.

2.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
3.

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H.

Clin Chem. 2009 Apr;55(4):765-73. doi: 10.1373/clinchem.2008.117952. Epub 2009 Feb 20.

4.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI.

Int J Cancer. 2015 Apr 15;136(8):1856-62. doi: 10.1002/ijc.29212. Epub 2014 Oct 8.

PMID:
25219358
5.
6.

KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.

Dijkstra S, Leyten GH, Jannink SA, de Jong H, Mulders PF, van Oort IM, Schalken JA.

Prostate. 2014 Sep;74(12):1222-30. doi: 10.1002/pros.22839. Epub 2014 Jul 7.

PMID:
25043536
7.

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, de Bono JS.

Lancet Oncol. 2012 Nov;13(11):1114-24. doi: 10.1016/S1470-2045(12)70372-8. Epub 2012 Oct 9.

PMID:
23059046
8.

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.

Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.

Eur Urol. 2011 Nov;60(5):897-904. doi: 10.1016/j.eururo.2011.07.011. Epub 2011 Jul 14.

9.

Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.

Amato RJ, Melnikova V, Zhang Y, Liu W, Saxena S, Shah PK, Jensen BT, Torres KE, Davis DW.

Urology. 2013 Jun;81(6):1303-7. doi: 10.1016/j.urology.2012.10.041. Epub 2013 Apr 23.

PMID:
23622774
10.

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.

Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ.

J Clin Oncol. 2001 Jun 15;19(12):3025-8.

PMID:
11408497
11.

[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].

Okubo Y, Ito T.

Hinyokika Kiyo. 1999 Jan;45(1):25-30. Japanese.

PMID:
10086262
12.

Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.

Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R.

BMC Cancer. 2010 Dec 3;10:666. doi: 10.1186/1471-2407-10-666.

13.

Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.

Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Thiel E, Foerster MH, Keilholz U.

Oncology. 2011;80(1-2):57-62. doi: 10.1159/000328283. Epub 2011 May 31.

PMID:
21625180
14.
15.

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.

Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL.

Int J Cancer. 2014 May 15;134(10):2284-93. doi: 10.1002/ijc.28561. Epub 2014 Jan 2.

PMID:
24166007
16.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

17.

Detection of circulating tumor cells in men with localized prostate cancer.

Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, et al.

J Clin Oncol. 1994 Dec;12(12):2634-9.

PMID:
7527455
18.

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Dec 1;13(23):7053-8.

19.

Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas.

Ghossein RA, Carusone L, Bhattacharya S.

In Vivo. 2000 Jan-Feb;14(1):237-50. Review.

PMID:
10757082
20.

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.

Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O.

J Natl Cancer Inst. 2013 Nov 20;105(22):1729-37. doi: 10.1093/jnci/djt280. Epub 2013 Oct 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk